The role of PET/CT in determining egfr mutation and ALK rearrangement in patients with lung adenocarcinoma

Aim: The aim of the present study is to evaluate the role of tumor FDG uptake in a non-invasive method and the use of positronemission tomography / computed tomography (PET/CT) in estimating epidermal growth factor receptor (EGFR) mutations andanaplastic lymphoma kinase (ALK) rearrangements in cases of adenocarcinoma of the lung.Material and Methods: A total of 115 patients with the diagnosis of an adenocarcinoma of the lung that underwent F-18 FDG PET/CTfor staging and whose EGFR mutation and ALK rearrangement status were analyzed were retrospectively analyzed. The associationof the PET parameters (SUVmax, SUVmean, MTV and TLG) of primary tumor with the molecular profile was analyzed.Results: EGFR mutations (EGFR+ group) and ALK rearrangements (ALK+ group) were found in 15 (13%) and 10 (8.7%) of 115 patients;and 90 patients (78.3%) had no EGFR mutation or ALK rearrangement (EGFR/ALK-). EGFR mutations were found to be significantlyhigher among the never-smoked group (p=0.009). No significant association was identified between the SUVmean, MTV and TLGvalues and EGFR mutations; however, patients with a low SUVmax value were found to have a significantly higher rate of EGFRmutation (p=0.034). No statistically significant differences were found between the ALK+ and ALK- group in terms of age, sex,cigarette smoking status, tumor stage, or PET parameters.Conclusion: Our study results suggest that a low SUVmax value in lung adenocarcinomas is associated with EGFR mutation, althoughthe diagnostic efficacy is not high.

PDF

___

1. Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: Epidemiology, etiology, and prevention. Clin Chest Med 2011;32:605-44.
2. Mitsudomi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 2007;98:1817-24.
3. Shaw AT, Engelman JA. ALK in lung cancer: Past, present, and future. J ClinOncol.2013;31:1105-11.
4. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
5. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
6. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-94.
7. Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J ThoracOncol 2013;8:823-59.
8. Leighl NB, Rekhtman N, Biermann WA, Huang J, MinoKenudson M, Ramalingam SS, et al. Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/international association for the study of lung cancer/ association for molecular pathology guideline. J ClinOncol 2014;32:3673-9.
9. Makinoshima H, Takita M, Matsumoto S, et al. Epidermal growth factor receptor (EGFR) signaling regulates global metabolic pathways in EGFR-mutated lung adenocarcinoma. J Biol Chem 2014;289:20813– 23.
10. De Rosa V, Iommelli F, Monti M, et al. Reversal of Warburg effect and reactivation of oxidative Phosphorylation by differential inhibition of EGFR signaling pathways in non-small cell lung cancer. Clin Cancer Res 2015;21:5110-20.
11. Mak RH, Digumarthy SR, Muzikansky A, Engelman JA, Shepard JA, Choi NC, et al. Role of 18F-fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non-small cell lung cancer. Oncologist 2011;16:319-26.
12. Na II, Byun BH, Kim KM, et al. 18F-FDG uptake and EGFR mutations in patients with non-small cell lung cancer: a single-institution retrospective analysis. Lung Cancer 2010;67:76-80.
13. Lv Z, Fan J, Xu J, et al. Value of 18F–FDG PET/CT for predicting EGFR mutations and positive ALK expression in patients with non-small cell lung cancer: a retrospective analysis of 849 Chinese patients. Eur J of Nucl Med and Mol Imaging 2018;45:735-50.
14. Lee EY, Khong PL, Lee VH, Qian W, Yu X, Wong MP. Metabolic Phenotype of Stage IV Lung Adenocarcinoma Relationship With Epidermal Growth Factor Receptor Mutation. Clin Nucl Med 2015;40:190-5.
15. Caicedo C, Garcia-Velloso MJ, Lozano MD, et al. Role of [18F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced nonsmall-cell lung cancer. Eur J Nucl Med Mol Imaging. 2014;41:2058-65.
16. Ko KH, Hsu HH, Huang TW, et al. Value of 18F-FDG uptake on PET/CT and CEA level to predict epidermal growth factor receptor mutations in pulmonary adenocarcinoma. Eur J Nucl Med Mol Imaging 2014;41:1889-97.
17. Huang CT, Yen RF, Cheng MF, et al. Correlation of F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value and EGFR mutations in advanced lung adenocarcinoma. Med Oncol 2010;27:9-15.
18. Lee SM, Bae SK, Jung SJ, et al. FDG uptake in non– small cell lung vancer is not an independent predictor of EGFR or KRAS mutation status. A Retrospective Analysis of 206 Patients. Clin Nucl Med 2015;40: 950- 8.
19. Yip SS, Kim J, Coroller TP, et al. Associations between somatic mutations and metabolic imaging phenotypes in non-small cell lung cancer. J Nucl Med 2017;58:569-76.
20. Apostolova I, Ego K, Steffen IG, et al. The asphericity of the metabolic tumour volume in NSCLC: correlation with histopathology and molecular markers. Eur J Nucl Med Mol Imaging 2016;43:2360-73.
21. Choi H, Paeng JC, Kim DW, et al. Metabolic and metastatic characteristics of ALK-rearranged lung adenocarcinoma on FDG PET/CT. Lung Cancer 2013;79:242-7.
22. Jeong CJ, Lee HY, Han J, et al. Role of Imaging Biomarkers in Predicting Anaplastic Lymphoma Kinase–Positive Lung Adenocarcinoma. Clin Nucl Med. 2015;40:34-9.
23. Ciernik IF, Dizendorf E, Baumert BG, Reiner B, Burger C, Davis JB, et al. Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): a feasibility study.Int. J. Radiation Oncology Biol Phys 2003;57:853-63.
24. Lee P, Weerasuriya DK, Lavori PW, et al. Metabolic tumor burden predicts for disease progression and death in lung cancer. Int J Radiation Oncology Biol Phys 2007;69:328-33.
25. Huang W, Zhou T, Ma L, et al. Standard uptake value and metabolic tumor volüme of 18F-FDG PET/CT predict short-term outcome early in the course of chemoradiotherapy in advanced non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2011;38:1628- 35.
26. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57.
27. Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014;371:2167-77.
28. 28. Han JY, Park K, Kim SW, Lee DH, Kim HY, Kim HT, et al. First- SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J ClinOncol 2012;30:1122-8.
29. Xu C, Zhou Q, Wu YL. Can EGFR-TKIs be used in first line treatment for advanced non-small cell lung cancer based on selection according to clinical factors? - a literature-based meta-analysis. J HematolOncol 2012;5:62.
30. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339-46.
31. Sequist LV, Bell DW, Lynch TJ, et al. Molecular predictors of response to epidermal growth factor receptor antagonists in nonsmall-cell lung cancer. J ClinOncol 2007;25:587-95.
32. Boch C, Kollmeier J, Roth A, et al. The frequency of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC): routine screening data for central Europe from a cohort study. BMJ Open 2013;3:002560.
33. Helland A, Skaug HM, Kleinberg L, Iversen ML, Rud AK, Fleischer T, et al. EGFR gene alterations in a Norwegian cohort of lung cancer patients selected for surgery. J ThoracOncol 2011;6:947-50.
34. Smits AJ, Kummer JA, Hinrichs JW, et al. EGFR and KRAS mutations in lung carcinomas in the Dutch population: increased EGFR mutation frequency in malignant pleural effusion of lung adenocarcinoma. Cell Oncol 2012;35:189-96.
35. Yang SH, Mechanic LE, Yang P, et al. Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer. Clin Cancer Res 2005;11:2106-10.
36. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-703.
37. Wong DW, Leung EL, So KK, et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 2009;115:1723-33.
38. Solomon B, Varella-Garcia M, Camidge DR. ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer. J ThoracOncol 2009;4:1450-4.
39. Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J ThoracOncol 2008;3:13-7.